Last reviewed · How we verify
NORTASE®
NORTASE is an enzyme-based therapeutic that degrades extracellular matrix components to improve drug penetration and immune cell infiltration in solid tumors.
NORTASE is an enzyme-based therapeutic that degrades extracellular matrix components to improve drug penetration and immune cell infiltration in solid tumors. Used for Solid tumors (in combination with immunotherapy or chemotherapy).
At a glance
| Generic name | NORTASE® |
|---|---|
| Sponsor | University of Leipzig |
| Drug class | Matrix-degrading enzyme / Tumor microenvironment modifier |
| Target | Extracellular matrix proteins (collagen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
NORTASE functions as a matrix-degrading enzyme, likely a collagenase or similar protease, designed to remodel the tumor microenvironment by breaking down collagen and other structural proteins. By reducing the physical barrier of the extracellular matrix, the drug aims to enhance penetration of chemotherapeutic agents and checkpoint inhibitors while facilitating immune cell infiltration into previously inaccessible tumor regions.
Approved indications
- Solid tumors (in combination with immunotherapy or chemotherapy)
Common side effects
- Infusion-related reactions
- Potential matrix degradation-related toxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NORTASE® CI brief — competitive landscape report
- NORTASE® updates RSS · CI watch RSS
- University of Leipzig portfolio CI